Glutamate is associated with a higher risk of seizures in patients with gliomas

Grants

Funding Acknowledgements

T. Yuen received scholarship support from the Royal Australasian College of Surgeons. A. Morokoff has received research support from the Australian National Health & Medical Research Council, The Brain Foundation, the Victorian Cancer Agency, and the Royal Melbourne Hospital Neuroscience Foundation. He has received travel and speaker honoraria from Medtronic, Stryker, and K2M. A. Bjorksten, G. D'Abaco, L. Paradiso, S. Finch, D. Wong, C. Reid, and K. Powell report no disclosures. K. Drummond has received research support from the Victorian Cancer Agency. M. Rosenthal is on the board of Cancer Trials Australia and has received funding from the National Health & Medical Research Council and the Victorian Cancer Agency. A. Kaye has received research support from the National Health and Medical Research Council and the Royal Melbourne Hospital Neuroscience Foundation. T. J. O'Brien has chaired a scientific advisory board for Janssen-Cilag EMEA; has received speaker honoraria from Janssen-Cilag EMEA and Sanofi-Aventis; and has received research support from UCB, Abbott, National Health and Medical Research Council of Australia, and the Royal Melbourne Hospital Neuroscience Foundation. Go to Neurology.org for full disclosures.Supported by the National Health and Medical Research Council of Australia (628301); The Melville Hughes Scholarship (to T. Y.); the John Lowenthal Surgical Scholarship, Royal Australasian College of Surgeons (to T. Y.); and the Royal Melbourne Hospital Neuroscience Foundation.